Pillars of growth
Heavy bet for R&D
as a future
growth engine
Heavy bet on R&D
as a future
growth engine
Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
CDMO
High production capacity with four the manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
817.7 Mn€
Operatig revenuesin 2022
264.0 Mn€
Sales for the Heparin Division in 2022(+9% vs 2021)
+90 countries
LMWH presence through strategic alliances with international partners
7 plants
For the third party, own and Investigational drug manufacture
403.5 Mn€
CDMO Sales in 2022 (+52% vs 2021)
42,85%
Porcentage of women on the Boards of Directors
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.